Auxly Cannabis Group (OTCMKTS:CBWTF) and Protalex (OTCMKTS:PRTX) are both small-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.
Insider & Institutional Ownership
0.2% of Protalex shares are held by institutional investors. 80.0% of Protalex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Auxly Cannabis Group and Protalex’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Auxly Cannabis Group||$580,000.00||598.06||-$51.68 million||N/A||N/A|
Protalex has lower revenue, but higher earnings than Auxly Cannabis Group.
This is a breakdown of recent ratings and recommmendations for Auxly Cannabis Group and Protalex, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Auxly Cannabis Group||0||0||0||0||N/A|
This table compares Auxly Cannabis Group and Protalex’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Auxly Cannabis Group||-652.13%||-21.42%||-15.06%|
Risk and Volatility
Auxly Cannabis Group has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Protalex has a beta of -1.03, suggesting that its share price is 203% less volatile than the S&P 500.
Protalex beats Auxly Cannabis Group on 6 of the 8 factors compared between the two stocks.
Auxly Cannabis Group Company Profile
Auxly Cannabis Group Inc. operates as a cannabis streaming company. It provides funding for cannabis production; and holds contractual rights and minority equity interest relating to the operation of cannabis facilities. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is headquartered in Vancouver, Canada.
Protalex Company Profile
Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.
Receive News & Ratings for Auxly Cannabis Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxly Cannabis Group and related companies with MarketBeat.com's FREE daily email newsletter.